Conference at the 6th ESOP Meeting, Budapest, 28 September 1998: The role of pharmacoepidemiology in pharmacovigilance

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue SUPPL. 1, 1999, Pages

  Abenhaim, Lucien ^a,b,c   Moore, Nicholas ^a   Bégaud, Bernard ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b MCGILL UNIVERSITY   (Canada)

^c Department of Pharmacoepidemiology ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; HUMAN; LAW; MEDICAL PRACTICE; METHODOLOGY; NORTH AMERICA; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

EID: 0032945076     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199904)8:1+3.0.CO;2-E     Document Type: Review

References (16)

1. Wiholm, B. E., Olsson, S., Moore, N. and Wood, S. Spontaneous reporting outside the US: principles and pitfalls. In: Pharmacoepidemiology. Strom, B. (Ed.), J. Wiley & Sons, New York, 1994.
2. Strom, B. Pharmacoepidemiology, J. Wiley & Sons, New York, 1994.
3. Dunlop, D. (Pharmacovigilance in the framework of recording and control of drugs in the United Kingdom). Therapie 1974; 29(6): 799-804.
4. Lagier, G., Efthymiou, M. L., Lechat, P. and Fournier, E. (Pharmacovigilance in the hospital. First results). Therapie 1974; 29(6): 805-810.
5. Lawson, D. H. Pharmacoepidemiology: a new discipline. British Medical Journal (Clinical Research Edition) 1984; 289: 940-941.
6. Abenhaim, L., Moride, Y., Brenot, F. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. New England Journal of Medicine 1996; 335(9): 609-616.
7. Wacholder, S., Silverman, D. T., McLaughlin, J. K. and Mandel, J. S. Selection of controls in case-control studies. II. Types of controls. American Journal of Epidemiology 1992; 135(9): 1029-1041.
8. Moore, N., Masson, H., Noblet, C. and Joannidès, R. What medicines do patients really take? A comparison of free form vs oriented questionnaires. Post Marketing Surveillance 1993; 7: 355-362.
9. van Staa, T. P., Abenhaim, L. and Leufkens, H. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. Journal of Clinical Epidemiology 1994; 47(2): 183-189.
10. Garcia Rodriguez, L. A. and Perez Gutthann, S. Use of the UK General Practice Research Database for pharmacoepidemiology. British Journal of Clinical Pharmacology 1998; 45(5): 419-425.
11. Jick, H., Jick, S. S. and Derby, L. E. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. British Medical Journal 1991; 302: 766-768.
12. Lerebours, G., Senant, J., Moore, N., Arnaud, F., David, P. and Ozenne, G. Evolution of peripheral nerve function in hypoxaemic COPD patients taking almitrine bismesylate: a prospective long-term study. Bulletin Européan de Physiopathologie Respiratoire 1987; 23(Suppl. 11): 203S-206S.
13. Lévesque, H., Moore, N. and Courtois, H. Reporting adverse drug reactions by proprietary name. Lancet 1991; 338: 393.
14. Rostin, M., Paux, G., Sorbette, F. et al. (Two epidemics of acute kidney failure caused by piromidic acid). Therapie 1988; 43(5): 426-427.
15. Capella, D., Laporte, J. R., Vidai, X. et al. European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study. European Journal of Clinical Pharmacology 1998; 53(5): 299-302.
16. ARME-Pharmacovigilance. Methodological Approaches in Pharmaco-epidemiology. Application to Spontaneous Reporting, Arme-Pharmacovigilance éditions, Bordeaux, 1993.